NOVARTIS - NVS Third Quarter Results Review- Going forward, NVS growth to remain unscathed by the looming patent expiries
NVS reported third quarter results today delivering robust sales growth (12% cc), and operating income growth (14%). The results are in line with our expectations, while going forward, the cost cutting initiatives (2000 jobs cuts in the US and Switzerland), growth from recently launched products (Gilenya, Lucentis, Galvus, Tasigna, Afinitor, Onbrez), growth from Alcon (7%cc), emerging markets (24% cc), Sandoz (biosimilars, respiratory generics), and pipeline products (QT1571, INC424, AG0178, SOM230, QVA149, AIN457) will allow NVS growth to continue unscathed by the looming patent expiries (Diovan, Zometa, Reclast, Exforge).
COMPANIES MENTIONED
NOVARTIS, NVS
NOVARTIS, NVS
